^
    Back
    Association details:
    Biomarker:MSI-H/dMMR + TMB-H + PD-L1 overexpression
    Cancer:Small Intestinal Carcinoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    The Oncologist
    Title:

    A Case of a Pathological Complete Response to Neoadjuvant Nivolumab Plus Ipilimumab in Periampullary Adenocarcinoma

    Published date:
    05/13/2021
    Excerpt:
    ...we report on a patient with known Lynch Syndrome and periampullary adenocarcinoma...harboring two MSH2 mutations, high microsatellite instability (MSI-high), high tumor mutational burden (TMB) and elevated PD-L1 expression achieved pathological complete response with neoadjuvant nivolumab plus ipilimumab....
    DOI:
    https://doi.org/10.1002/onco.13821